- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00417196
Safety, Pharmacodynamic and Pharmacokinetic Effects of QAX576 in Healthy Volunteers.
September 30, 2010 updated by: Novartis
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Single Escalating Doses of Intravenous QAX576
This study is designed to evaluate the safety, pharmacodynamic and pharmacokinetic effects of individual escalating intravenous doses of QAX576 in healthy volunteers.
Study Overview
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
East Hanover, New Jersey, United States, 07936-1080
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male and female subjects age 18 to 45 years, inclusive, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
- Only surgically sterilized female subjects with procedure performed at least 6 months prior to screening with supportive clinical documentation are allowed to participate in this study.
- Male subjects must be using a double-barrier local contraception, i.e., spermicidal gel plus condom, for the entire duration of the study, up to Study Completion visit (i.e., refrain from fathering a child in the 4 months following last study drug administration).
- Vital signs should be within the following ranges:
Oral body temperature 35.0-37.5°C. Supine systolic blood pressure, 90-140 mm Hg. Supine diastolic blood pressure, 50-90 mm Hg. Supine pulse rate, 50-90 beats per minute (bpm).
- When blood pressure and pulse will be taken again after 3 minutes standing, there shall be no more than a 20 mm Hg drop in systolic or 10 mm Hg drop in diastolic blood pressure and increase in heart rate (>20 bpm) associated with clinical manifestation of postural hypotension.
- Body mass index (BMI) must be within the range of 18 to 28 kg/m2. Subjects must weigh between 50 and 100 kg (inclusive).
Exclusion Criteria:
- Smokers (use of tobacco products in the previous 3 months). Smokers will be who reports tobacco use or has a urine cotinine greater than 500 ng/mL.
- Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter (OTC) medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to dosing. Acetaminophen is acceptable with clinical documentation.
- Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations.
- Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
- Significant illness within 2 weeks prior to dosing.
- A past medical history of clinically significant ECG abnormalities.
- History of autonomic dysfunction or acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated) or clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs similar to the study drug..
- History or presence of any surgical or medical condition which, in the opinion of the investigator, may jeopardize the subject in case of participation in the study, including hepatic, hematological, or immunological, disorders..
- History of clinical schistosomiasis or travel within the preceding 6 months to an area with endemic schistosomiasis, including but not limited to Southeast Asia and Northwest Africa
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety and tolerability of single escalating doses of QAX576 as assessed by vital signs, electrocardiogram (ECG), adverse events, laboratory evaluations, up to 96 hours after drug administration, and telemetry up until 24 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
---|
Exploration of pharmacokinetics of QAX576 and its pharmacodynamic effects on interleukin 13 (IL-13) concentration data. Samples collection at pre-dose and up to 48 hours post-dose.
|
Assess the immunogenicity of QAX576 in healthy subjects.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2006
Study Completion (Actual)
August 1, 2007
Study Registration Dates
First Submitted
December 28, 2006
First Submitted That Met QC Criteria
December 28, 2006
First Posted (Estimate)
December 29, 2006
Study Record Updates
Last Update Posted (Estimate)
October 1, 2010
Last Update Submitted That Met QC Criteria
September 30, 2010
Last Verified
September 1, 2010
More Information
Terms related to this study
Other Study ID Numbers
- CQAX576A2101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on QAX576
-
Novartis PharmaceuticalsTKL Research, Inc.; Virginia Clinical Research, Inc.; Dermatology Consulting... and other collaboratorsTerminated
-
Novartis PharmaceuticalsCompletedEosinophilic EsophagitisUnited States
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedAsthmaRussian Federation, United Kingdom
-
Novartis PharmaceuticalsTerminatedIdiopathic Pulmonary FibrosisUnited States, United Kingdom
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedAsthmaGermany, United States, Poland, Belgium, Argentina, Russian Federation, Czechia
-
Novartis PharmaceuticalsTerminatedPulmonary Fibrosis Secondary to Systemic Sclerosis
-
NovartisWithdrawn
-
NovartisCompletedAllergic RhinitisUnited Kingdom, Germany